Stablix
About:
Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS).
Website: https://www.stablix.com/
Twitter/X: StablixInc
Top Investors: Alexandria Real Estate Equities, New Enterprise Associates, Cormorant Asset Management, Euclidean Capital, Versant Ventures
Description:
Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). The company’s resorted platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity. Stablix initially is leveraging the platform to develop programs to treat rare diseases, cancer, and immunological disorders.
$63M
New York, New York, United States
2021-01-01
info(AT)stablix.com
Brian Bowman, Carlo Rizzuto, Henry Colecraft, Kevin Sprott, Scott Kanner
11-50
2021-06-03
Private
© 2025 bioDAO.ai